Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

Inclusion Criteria: * Histological confirmation of well-differentiated Grade 1/Grade 2 NET from gastrointestinal, pancreatic, pulmonary or unknown primary sites. * Metastatic or locally advanced and unresectable disease, measurable by images * Disease progression by RECIST 1.1 in the last 6 months assessed by local investigators * At least one previous line of systemic treatment (suspended for more than 3 weeks). * Eastern Cooperative Oncology Group (ECOG) 0-2 o Good organ function: * Hemoglobin \> 8 g/dL * Neutrophils ≥ 1,500/mm³ * Platelets \> 90,000/mm³ * Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN \[upper limit of normal\] or ≤ 5 x ULN for patients with liver metastases * Bilirubin ≤ 1.5 x ULN, creatinine \< 1.5 mg/dL Exclusion Criteria: * Aggressive disease requiring cytotoxic therapy * Severe/uncontrolled comorbid conditions that deem participant unfit for everolimus therapy, as per investigators' judgement. * MiNEN